SULT4A1-1 Haplotype Biomarker for Antipsychotic Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychotic disorders, such as schizophrenia and bipolar disorders, face challenges in identifying the optimal antipsychotic medication for individual patients due to individual differences in drug response and side effects, leading to increased costs, medication switching, and adverse effects.
Innovation Solution
The use of the SULT4A1-1 haplotype as a biomarker to determine the most appropriate antipsychotic treatment plan by identifying whether a patient has the SULT4A1-1 haplotype, which influences the response to specific medications like olanzapine or risperidone, through genetic testing and analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antipsychotic medications are prescribed without genetic testing, then treatment can be initiated quickly, but treatment efficacy is suboptimal and side effects occur due to inability to predict individual response
Solution Approach 1:
The patent applies preliminary action by conducting genetic testing before initiating antipsychotic treatment to identify the SULT4A1-1 haplotype status. This pre-test determines the patient's metabolic profile and predicts response to specific medications (olanzapine vs. risperidone), allowing the clinician to select the optimal medication in advance rather than attempting multiple trials after the fact.
Solution Approach 2:
The patent implements feedback by using genetic test results to guide medication selection and by establishing a framework for monitoring treatment response. The SULT4A1-1 haplotype information provides feedback about the patient's metabolic characteristics, enabling personalized treatment decisions and adjusting therapy based on predicted and actual response patterns.
2Reliability
If patients switch medications multiple times to find effective treatment, then treatment efficacy may be improved, but costs increase and patient hardship increases
Solution Approach 1:
The patent prevents multiple medication switches by performing genetic testing before treatment initiation to identify the SULT4A1-1 haplotype. This preliminary identification allows selection of the most likely effective medication from the start, reducing or eliminating the need for subsequent switching and the associated costs and hardships.
3Reliability
If polypharmacy is used to achieve adequate treatment response, then treatment efficacy improves, but adverse effects and drug interactions increase
Solution Approach 1:
The patent extracts the key genetic information (SULT4A1-1 haplotype status) that determines metabolic response to antipsychotics. By identifying this specific genetic marker, the system can select the optimal single medication that matches the patient's metabolic profile, eliminating the need for polypharmacy and reducing associated adverse effects and drug interactions.
Data Source
AI summary
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.